Creating New and Improved Anti-Cancer Medicines
Catalytic and Stereoselective C-C-Heteroatom Bond Forming Reactions
This research is developing new chemical methods to more efficiently create different versions of existing drugs and natural compounds, especially those used to fight cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11121046 on NIH RePORTER |
What this research studies
Developing new medicines, particularly for conditions like cancer, often involves complex and time-consuming chemical processes to create specific drug variations. Our goal is to find simpler, faster, and more affordable ways to make these important drug molecules. We are working on new chemical reactions that can directly modify existing drug structures, allowing us to quickly generate many different versions. These new versions can then be used to better understand how drugs work, improve their effectiveness, or even create entirely new treatment options.
Who could benefit from this research
Good fit: This foundational chemistry research does not involve direct patient participation, but future patients with cancer could benefit from the more efficient development of new drugs.
Not a fit: Patients would not receive direct medical benefit from participating in this laboratory-based chemical synthesis research.
Why it matters
Potential benefit: If successful, this work could speed up the discovery and development of new anti-cancer agents and other important medicines, potentially leading to more effective treatments for patients.
How similar studies have performed: While the direct transformation methods explored here are challenging, similar chemical strategies have shown promise in making drug development more efficient.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Wasa, Masayuki — University of Florida
- Study coordinator: Wasa, Masayuki
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.